Document:

Exhibit 10.1

October 30, 2018

 

Steven Sherman

c/o Ekso Bionics Holdings, Inc.

1414 Harbour Way South, Suite 1201

Richmond, California 98404

 

RE: Offer Letter - Executive Chairman

 

Dear Steven,

 

This letter (the “Agreement”) confirms the
agreement between you and Ekso Bionics Holdings, Inc. (the “Company”) with respect to your employment with the
Company. You will serve as the Executive Chair of the Company commencing on October 30, 2018 (the “Effective Date”)
and continuing through the second anniversary of the Effective Date, unless earlier terminated as set forth herein. You will be
subject to the supervision of, and will have such authority as is delegated by, the Chief Executive Officer of the Company. You
will devote such of your business efforts and time to the Company as you shall reasonably determine are required to carry out your
duties, which duties include the strategic business development of the Company and its subsidiaries, it being understood that the
role of Executive Chair is not intended to be full time, but that it is expect that you will devote a significant amount of your
business efforts to this role.

 

As of the Effective Date, you will be paid an annual base salary
of $100,000, less payroll deductions and all required withholdings, paid in accordance with the Company’s standard payroll
practices. You will be eligible for standard benefits including medical insurance, according to standard Company policy as amended
from time to time.

 

The Company will recommend
that the Compensation Committee of the Board approve a grant to you in the form of an option under the Company’s Amended
and Restated 2014 Equity Incentive Plan to purchase Four Hundred Thousand (400,000) shares of common stock of the Company. The
option will issued in the form of a non-qualified stock option and the exercise price shall be equal to the closing price of one
share of common stock on the Nasdaq Capital Market on the date the grant is approved by the Compensation Committee of the Board.
The option shall become exercisable with respect to the shares of common stock covered thereby in eight (8) equal installments
every three months following the Effective Date, with the first such installment vesting on the date that is three months after
the effective date (or if there is no such date in such month, then the last day of such month), subject to you continuing to provide
services to the Company (or its parent or subsidiary) as an executive officer and as a director on each such vesting date.

 

Your employment hereunder
shall be entirely “at-will,” meaning that either you or the Company may terminate such employment relationship, at
any time for any reason or for no reason at all, by delivery of written notice of employment termination to the other party.

 

The Company reimburses employees for certain
reasonable and documented business expenses. Please refer to the Company’s travel & expense policy for additional information.
As a Company employee, you will be expected to abide by Company policies and procedures, and acknowledge in writing that you have
read such policies, which may be revised, amended or supplemented by Company at any time.

 

    -1- 

     

    

 

 

 

In addition, you shall
execute and comply with the terms of any restrictive covenants as the Company may request from its executive and management employees
from time to time on a reasonable and uniform basis including, without limitation, the terms of the Employee Invention Assignment
and Confidentiality Agreement in the form or substantially the form appended to this Agreement as Exhibit A.

 

The employment terms
in this letter supersede any other agreements or promises made to you by anyone, whether verbal or written, and comprise the final,
complete and exclusive agreement between you and the Company, subject only to the terms of the definitive agreements referenced
herein. The terms of this letter agreement and the resolution of any disputes will be governed by California law.

 

If you wish to accept employment at the Company under the terms
described above, please sign and return to Jack Peurach, Chief Executive Officer, via email at jack@eksobionics.com.

 

We look forward to your favorable reply and to a productive
and enjoyable work relationship.

  

 

Very truly yours,

 

EKSO BIONICS HOLDINGS, INC.

 

 

 

	By:	/s/ Jack Peurach	 	 
	Title:	Chief Executive Officer	 	 
	I have read and accept this offer letter:
	 	 	 	 
	 	 	 	 
	/s/ Steven Sherman	 	 
	Steven Sherman	 	 
	 	 	 	 
	 	 	 	 
	Dated:	October 30, 2018	 	 

 

 

    -2- 

     

    

 

EXHIBIT A

 

Employee Invention Assignment and Confidentiality
Agreement

 

 

EMPLOYEE
INVENTION ASSIGNMENT and CONFIDENTIALITY AGREEMENT

 

In consideration of, and as a condition
of my employment with Ekso Bionics Holdings, Inc., a Nevada corporation with its principal offices in the State of California (the
“Company”), or any of its subsidiary or affiliated entities, I, ____________________,
as the “Employee” signing this Employee Invention Assignment and Confidentiality
Agreement (this “Agreement”), hereby represent to the Company, and
the Company and I hereby agree as follows:

 

1.                 
Purpose of Agreement. I understand that the Company, together
with its subsidiary and affiliated entities, whether or not separately incorporated (each, including the Company, referred to hereinafter
as an “Ekso Bionics Entity” and collectively as the “Ekso Bionics Entities”) is engaged in
a continuous program of research, development, production and/or marketing in connection with its current and projected business
and that it is critical for the Ekso Bionics Entities to preserve and protect their proprietary information, their rights in certain
inventions and works and in related intellectual property rights. Accordingly, I am entering into this Agreement, whether or not
I am expected to create inventions or other works of value for the Ekso Bionics Entities or any one or more of them. As used in
this Agreement, “Inventions” means inventions, improvements, designs, original works of authorship, formulas,
processes, compositions of matter, computer software programs, databases, mask works, confidential information and trade secrets.

 

2.                 
Disclosure of Inventions. I will promptly disclose in
confidence to the Company, or to any person designated by it, all Inventions that I make, create, conceive or first reduce to practice,
either alone or jointly with others, during the period of my employment, whether or not in the course of my employment, and whether
or not patentable, copyrightable or protectable as trade secrets.

 

3.                 
Work for Hire; Assigned Inventions. I acknowledge and
agree that any copyrightable works prepared by me within the scope of my employment will be “works made for hire” under
the Copyright Act and that the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company) will
be considered the author and owner of such copyrightable works. I agree that all Inventions that I make, create, conceive or first
reduce to practice during the period of my employment, whether or not in the course of my employment, and whether or not patentable,
copyrightable or protectable as trade secrets, and that (i) are developed using equipment, supplies, facilities or trade secrets
of the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company); (ii) result from work
performed by me for any Ekso Bionics Entity; or (iii) relate to the business or actual or demonstrably anticipated research
or development of any Ekso Bionics Entity (the “Assigned Inventions”), will be the sole and exclusive
property of the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company).

 

4.                 
Excluded Inventions and Other Inventions. Attached hereto as Exhibit A
is a list describing all existing Inventions, if any, that may relate to the business or actual or demonstrably anticipated research
or development of any Ekso Bionics Entity and that were made by me or acquired by me prior to the Effective Date (as defined in
Section 25, below), and which are not to be assigned to the Company (“Excluded Inventions”). If no such
list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to the business
or actual or demonstrably anticipated research or development of any Ekso Bionics Entity. For purposes of this Agreement, “Other
Inventions” means Inventions in which I have or may have an interest, as of the Effective Date or thereafter, other
than Assigned Inventions and Excluded Inventions. I acknowledge and agree that if, in the scope of my employment with any Ekso
Bionics Entity or Entities, I use any Excluded Inventions or any Other Inventions, or if I include any Excluded Inventions or Other
Inventions in any product or service of any Ekso Bionics Entity or if my rights in any Excluded Inventions or Other Inventions
may block or interfere with, or may otherwise be required for, the exercise by any Ekso Bionics Entity of any rights assigned to
any Ekso Bionics Entity under this Agreement, I will immediately so notify the Company (or such other Ekso Bionics Entity or Entities
as may be designated by the Company) in writing. Unless the Company (or such other Ekso Bionics Entity or Entities as may be designated
by the Company) and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to the
Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company), in such circumstances (whether or
not I give the Company notice as required above), a perpetual, irrevocable, nonexclusive, transferable, world-wide, royalty-free
license to use, disclose, make, sell, offer for sale, import, copy, distribute, modify and create works based on, perform, and
display such Excluded Inventions and Other Inventions, and to sublicense third parties in one or more tiers of sub-licensees with
the same rights.

 

    -3- 

     

    

 

5.                 
Exception to Assignment. I understand that the Assigned
Inventions will not include, and the provisions of this Agreement requiring assignment of inventions to the Company do not apply
to, any invention that qualifies fully for exclusion under the provisions of Section 2870 of the California Labor Code, which are
attached hereto as Exhibit B.

 

6.                 
Assignment of Rights. I agree to assign, and do hereby
irrevocably transfer and assign, to the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company):
(i) all of my rights, title and interests in and with respect to any Assigned Inventions; (ii) all patents, patent applications,
copyrights, mask works, rights in databases, trade secrets, and other intellectual property rights, worldwide, in any Assigned
Inventions, along with any registrations of or applications to register such rights; and (iii) to the extent assignable, any
and all Moral Rights (as defined below) that I may have in or with respect to any Assigned Inventions. I also hereby forever waive
and agree never to assert any Moral Rights I may have in or with respect to any Assigned Inventions and any Excluded Inventions
or Other Inventions licensed to the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company)
under Section 4, even after termination of my employment with all Ekso Bionics Entities. “Moral Rights”
means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, to withdraw
from circulation or control the publication or distribution of a work, and any similar right, regardless of whether or not such
right is denominated or generally referred to as a “moral right.” 

 

7.                 
Assistance. I will assist the Company, and each other
Ekso Bionics Entity as may be designated by the Company, in every proper way to obtain and enforce for the Ekso Bionics Entities,
or any one or more of such entities, all patents, copyrights, mask work rights, trade secret rights and other legal protections
for the Assigned Inventions, worldwide. I will execute and deliver any documents that the Company (or such other Ekso Bionics Entity
or Entities as may be designated by the Company) may reasonably request from me in connection with providing such assistance. My
obligations under this section will continue beyond the termination of my employment with any one or more of the Ekso Bionics Entities;
provided that the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company) agrees to compensate
me at a reasonable rate after such termination for time and expenses actually spent by me at the request of an Ekso Bionics Entity
in providing such assistance. I hereby appoint the Secretary of the Company as my attorney-in-fact to execute documents on my behalf
for this purpose. I agree that this appointment is coupled with an interest and will not be revocable.

 

8.                 
Proprietary Information. I understand that my employment
by an Ekso Bionics Entity creates a relationship of confidence and trust with respect to any information or materials of a confidential
or secret nature that may be made, created or discovered by me or that may be disclosed to me by the applicable Ekso Bionics Entity
or a third party in relation to the business of the Ekso Bionics Entities, jointly or severally, or to the business of any parent,
subsidiary, affiliate, customer or supplier of an Ekso Bionics Entity, or any other party with whom an Ekso Bionics Entity agrees
to hold such information or materials in confidence (the “Proprietary Information”). Without limitation
as to the forms that Proprietary Information may take, I acknowledge that Proprietary Information may be contained in tangible
material such as writings, drawings, samples, electronic media, or computer programs, or may be in the nature of unwritten knowledge
or know-how. Proprietary Information includes, but is not limited to, Assigned Inventions, marketing plans, product plans, designs,
data, prototypes, specimens, test protocols, laboratory notebooks, business strategies, financial information, forecasts, personnel
information, contract information, customer and supplier lists, and the non-public names and addresses of the customers and suppliers
of any Ekso Bionics Entity, their buying and selling habits and special needs.

 

9.                 
Confidentiality. At all times, both during my employment
and after its termination, I will keep and hold all Proprietary Information in strict confidence and trust. I will not use or disclose
any Proprietary Information without the prior written consent of the Company (or such other Ekso Bionics Entity or Entities as
may be designated by the Company) in each instance, except as may be necessary to perform my duties as an employee of an Ekso Bionics
Entity for the benefit of any Ekso Bionics Entity. Upon termination of my employment with an Ekso Bionics Entity, I will promptly
deliver to the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company) all documents and materials
of any nature pertaining to my work with all Ekso Bionics Entities, and I will not take with me or retain in any form any documents
or materials or copies containing any Proprietary Information.

 

10.             
Physical Property. All documents, supplies, equipment
and other physical property furnished to me by any Ekso Bionics Entity or produced by me or others in connection with my employment
will be and remain the sole property of the Company (or such other Ekso Bionics Entity or Entities as may be designated by the
Company). I will return to the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company) all
such items when requested by the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company), excepting
only my personal copies of records relating to my employment or compensation and any personal property I bring with me to my employment
with an Ekso Bionics Entity and designate as such. Even if the Company (or such other Ekso Bionics Entity or Entities as may be
designated by the Company) does not so request, I will upon termination of my employment return to the Company (or such other Ekso
Bionics Entity or Entities as may be designated by the Company) all Ekso Bionics Entity property, and I will not take with me or
retain any such items.

 

    -4- 

     

    

 

11.             
No Breach of Prior Agreements. I represent that my performance
of all the terms of this Agreement and my duties as an employee of any one or more Ekso Bionics Entities will not breach any invention
assignment, proprietary information, confidentiality, non-competition, or other agreement with any former employer or other party.
I represent that I will not bring with me to any Ekso Bionics Entity or use in the performance of my duties for any such entity
any documents or materials or intangibles of my own or of a former employer or third party that are not generally available for
use by the public or have not been legally transferred to an Ekso Bionics Entity.

 

12.             
“At Will” Employment. I understand that this
Agreement does not constitute a contract of employment or obligate the Company or any other Ekso Bionics Entity to employ me for
any stated period of time. I understand that I am an “at will” employee of any Ekso Bionics Entity and that my employment
can be terminated at any time, with or without notice and with or without cause, for any reason or for no reason, by either the
Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company) or by me. I acknowledge that any statements
or representations to the contrary are ineffective, unless put into a writing signed by the Company (or such other Ekso Bionics
Entity or Entities as may be designated by the Company). I further acknowledge that my participation in any stock option or benefit
program is not to be construed as any assurance of continuing employment for any particular period of time.

 

13.             
Company Opportunities; Duty Not to Compete. During the
period of my employment, I will at all times devote my best efforts to the interests of the Ekso Bionics Entities, and I will not,
without the prior written consent of the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company),
engage in, or encourage or assist others to engage in, any other employment or activity that: (i) would divert from the Ekso Bionics
Entities any business opportunity in which any one or more of the Ekso Bionics Entities can reasonably be expected to have an interest;
(ii) would directly compete with, or involve preparation to compete with, the current or future business of any one or more
of the Ekso Bionics Entities; or (iii) would otherwise conflict with the interests of any Ekso Bionics Entity or could cause a
disruption of its operations or prospects.

 

14.             
Non-Solicitation of Employees/Consultants. During my employment
with any one or more of the Ekso Bionics Entities and for a one (1) year period thereafter, I will not directly or indirectly solicit
away employees or consultants of any Ekso Bionics Entity for my own benefit or for the benefit of any other person or entity, nor
will I encourage or assist others to do so.

 

15.             
Use of Name & Likeness. I hereby authorize the Company
(or such other Ekso Bionics Entity or Entities as may be designated by the Company) to use, reuse, and to grant others the right
to use and reuse, my name, photograph, likeness (including caricature), voice, and biographical information, and any reproduction
or simulation thereof, in any form of media or technology now known or hereafter developed, both during and after my employment,
for any purposes related to the business(es) of any one or more of the Ekso Bionics Entities, such as marketing, advertising, credits,
and presentations.

 

    -5- 

     

    

 

16.             
Notification. I hereby authorize the Company (or such
other Ekso Bionics Entity or Entities as may be designated by the Company), during and after the termination of my employment with
any Ekso Bionics Entity, to notify third parties, including, but not limited to, actual or potential customers or employers, of
the terms of this Agreement and my responsibilities hereunder.

 

17.             
Injunctive Relief. I understand that a breach or threatened
breach of this Agreement by me may cause one or more Ekso Bionics Entities to suffer irreparable harm and that the affected Ekso
Bionics Entity/ies will therefore be entitled to injunctive relief to enforce this Agreement.

 

18.             
Governing Law; Severability.  This Agreement is intended
to supplement, and not to supersede, any rights any Ekso Bionics Entity may have in law or equity with respect to the duties of
its employees and the protection of its trade secrets. This Agreement will be governed by and construed in accordance with the
laws of the State of California without giving effect to any principles of conflict of laws that would lead to the application
of the laws of another jurisdiction. If any provision of this Agreement is invalid, illegal or unenforceable in any respect, such
provision will be enforced to the maximum extent possible, given the fundamental intentions of the parties when entering into this
Agreement. To the extent such provision cannot be so enforced, it will be stricken from this Agreement and the remainder of this
Agreement will be enforced as if such invalid, illegal or unenforceable provision had never been contained in this Agreement.

 

19.             
Counterparts. This Agreement may be executed in any number
of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together will constitute
one and the same agreement.

 

20.             
Entire Agreement. This Agreement and the documents referred
to herein constitute the entire agreement and understanding of the parties with respect to the subject matter of this Agreement,
and supersede all prior understandings and agreements, whether oral or written, between the parties hereto with respect to such
subject matter.

 

21.             
Amendment and Waiver. This Agreement may be amended only
by a written agreement executed by each of the parties to this Agreement. No amendment or waiver of, or modification of any obligation
under, this Agreement will be enforceable unless specifically set forth in a writing signed by the party against which enforcement
is sought. A waiver by either party of any of the terms and conditions of this Agreement in any instance will not be deemed or
construed to be a waiver of such term or condition with respect to any other instance, whether prior, concurrent or subsequent.

 

22.             
Successors and Assigns; Assignment. Except as otherwise
provided in this Agreement, this Agreement, and the rights and obligations of the parties hereunder, will bind and benefit the
parties and their respective successors, assigns, heirs, executors, administrators, and legal representatives. The Company may
assign any of its rights and obligations under this Agreement. I understand that I will not be entitled to assign or delegate this
Agreement or any of my rights or obligations hereunder, whether voluntarily or by operation of law, except with the prior written
consent of the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company).

 

23.             
Further Assurances. The parties will execute such further
documents and instruments and take such further actions as may be reasonably necessary to carry out the purposes and intent of
this Agreement. Upon termination of my employment with all Ekso Bionics Entities, I will execute and deliver a document or documents
in a form reasonably requested by the Company (or such other Ekso Bionics Entity or Entities as may be designated by the Company)
confirming my agreement to comply with the post-employment obligations contained in this Agreement. 

 

24.             
Acknowledgement. I certify and acknowledge that I have
carefully read all of the provisions of this Agreement and that I understand and will fully and faithfully comply with this Agreement.

 

    -6- 

     

    

 

25.             
Effective Date of Agreement. This Agreement is and will
be effective on and after the first day of my employment by an Ekso Bionics Entity, which is ________________, _______________,
20__ (the “Effective Date”). 

 

	Company:  Ekso Bionics Holdings, Inc.	 	Employee:  
	 	 	 
	By:	
	 	

	 	 	 	Signature
	 	 	 	 
	Name:	
	 	

	 	 	 	Name (Please Print full legal name)
	 	 	 	 
	Title:	
	 	
        

        

	 	 	 	Date of Signature

 

    -7- 

     

    

 

Exhibit
A

 

LIST OF
EXCLUDED INVENTIONS UNDER SECTION 4

 

	 	 	 	 	Identifying Number
	Title	 	Date	 	or Brief Description

 

 

 

 

 

 

 

 

 

 

	 	 	 No inventions, improvements, or original works of authorship
	 	 	Additional sheets attached

 

	 	 	 
	Signature of Employee: 	 	 
	 	 	 
	Print Name of Employee: 	 	 
	 	 	 
	Date: 	 	 

 

 

 

    -8- 

     

    

 

Exhibit
B

 

CALFORNIA
LABOR CODE 2870 NOTICE:

 

California Labor Code Section 2870
provides as follows:

 

Any provision in an employment
agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or
her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s
equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) relate at the time
of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated
research or development of the employer; or (2) result from any work performed by the employee for the employer. To the extent
a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required
to be assigned under California Labor Code Section 2870(a), the provision is against the public policy of this state and is
unenforceable.

 

 

 

2352224.3

 

    -9-EX-4.1

 Exhibit 4.1 

CA, INC. 
 2011 INCENTIVE
PLAN 
 Effective as of August 3, 2011, as amended and restated as of November 5, 2018 

ARTICLE I. 
 ESTABLISHMENT AND
PURPOSE 
 1.1    Purpose. The purpose of this CA, Inc. 2011 Incentive Plan (the
“Plan”) is to enable Broadcom Inc. or any successor thereto (the “Company”) to achieve superior financial performance, as reflected in the performance of its Common Stock and other key financial or operating
indicators by (i) providing incentives and rewards to certain Employees and Consultants who are in a position to contribute to the success and long-term objectives of the Company, (ii) aiding in the recruitment and retention of Employees
and (iii) providing Employees and Consultants an opportunity to acquire or expand equity interests in the Company, thus aligning the interests of such Employees and Consultants with those of the Company’s shareholders. Towards these
objectives, the Plan provides for the grant of Annual Performance Bonuses, Stock Options, Restricted Stock and Other Equity-Based Awards. 

1.2    Effective Date; Shareholder Approval; Amendment. The Plan is effective as of August 3,
2011 (the “Effective Date”). On July 11, 2018 (the “Merger Agreement Signing Date”), CA, Inc. entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Company, and Collie
Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of the Company, pursuant to which, CA, Inc. became become a wholly owned subsidiary of the Company upon the completion of the transactions contemplated by the Merger Agreement
(the “Merger Effective Time”). 
 ARTICLE II. 

DEFINITIONS 
 For purposes
of the Plan, the following terms shall have the following meanings, unless another definition is clearly indicated by particular usage and context: 

2.1    “Annual Performance Bonus” means an Award described in Section 4.4 of
the Plan. 
 2.2    “Award” means any form of incentive or performance award
granted under the Plan, whether singly or in combination, to a Participant pursuant to such terms, conditions, restrictions and/or limitations (if any) as the Committee may establish and as set forth in the applicable Award Agreement. Awards granted
under the Plan may consist of: 
 (a)    “Annual Performance Bonuses” awarded
pursuant to Section 4.4; 
 (b)    “Long-Term Performance Bonuses” awarded
pursuant to Section 4.5; 
 (c)    “Restricted Stock” awarded pursuant to
Section 4.6; 
 (d)    “Stock Options” awarded pursuant to Section 4.7;
and 
 (e)    “Other Equity-Based Awards” awarded pursuant to Section 4.8.

 2.3    “Award Agreement” means the document issued, either in writing or by
electronic means, by the Company to a Participant evidencing the grant of an Award. 

 2.4    “Board” means the Board of
Directors of the Company. 
 2.5    “Cause” means (a) if the Participant has
an effective employment agreement with the Company or any of its Subsidiaries, or participates in CA, Inc.’s Change in Control Severance Policy (the “CIC Severance Policy”), in each case, immediately prior to the Merger
Effective Time, the definition used in such employment agreement or in the CIC Severance Policy as in effect on the Merger Effective Time, and if there are “cause” definitions in both such employment agreement and the CIC Severance Policy,
the definition in the CIC Severance Policy shall control or (b) if the Participant does not have an effective employment agreement and does not participate in the CIC Severance Policy, in either case, immediately prior to the Merger Effective
Time, termination for misconduct, poor performance, or violation of any Company policy or procedure. By way of example, for purposes of clause (b), termination for Cause includes, but is not limited to: (1) dishonesty, including theft;
(2) insubordination; (3) job abandonment; (4) willful refusal to perform the employee’s job; (5) violation of the terms of the Company’s Employment and Confidentiality Agreement; (6) violation of the Company’s
policies on discrimination, unlawful harassment or substance abuse; (7) violation of the Company’s Work Rules, (8) violation of the Company’s Workplace Violence Policy; or (9) excessive absenteeism. 

2.6    “Change in Control” means the occurrence of any of the following events: 

(a)    individuals who, on the Effective Date of the Plan, constitute the Board (the “Incumbent Directors”)
cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the Effective Date of the Plan whose election or nomination for election was approved by a vote of a majority of the
Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent
Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened
solicitation of proxies or consents by or on behalf of any person other than the Board shall be deemed to be an Incumbent Director until the second anniversary of such election; 

(b)    any “person” (as such term is defined in Section 3(a)(9) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company’s then outstanding securities eligible to vote generally in the election of directors (the “Company Voting
Securities”); provided, however, that the event described in this paragraph (b) shall not be deemed to be a Change in Control by virtue of any of the following acquisitions: (A) by the Company or any subsidiary, (B) by any
employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary, (C) by any underwriter temporarily holding securities pursuant to an offering of such securities, (D) pursuant to a Non-Qualifying Transaction (as defined in paragraph (c) below), or (E) a transaction (other than one described in paragraph (c) below) in which Company Voting Securities are acquired from the Company,
if a majority of the Incumbent Directors approve a resolution providing expressly that the acquisition pursuant to this clause (E) does not constitute a Change in Control under this paragraph (b); 

(c)    the consummation of a merger, consolidation, statutory share exchange, reorganization, sale of all or substantially
all the Company’s assets or similar form of corporate transaction involving the Company or any of its subsidiaries that requires the approval of the Company’s stockholders, whether for such transaction or the issuance of securities in the
transaction (a “Business Combination”), unless immediately following such Business Combination: (A) at least 60% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving

  
 2 

 
Corporation”), or (y) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of at least 95% of the voting securities eligible to elect directors
of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which such Company
Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof
immediately prior to the Business Combination, (B) no person (other than any employee benefit plan (or related trust) sponsored or maintained by the Surviving Corporation or the Parent Corporation), is or becomes the beneficial owner, directly
or indirectly, of 35% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) and (C) at least a majority of
the members of the board of directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) following the consummation of the Business Combination were Incumbent Directors at the time of the Board’s
approval of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a
“Non-Qualifying Transaction” and any Business Combination which does not satisfy all of the criteria specified in (A), (B) and (C) shall be deemed a “Qualifying Transaction”); or 

(d)    the stockholders of the Company approve a plan of complete liquidation or dissolution of the Company. 

Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because any person acquires beneficial ownership of
more than 35% of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Company or its affiliates which reduces the number of Company Voting Securities outstanding; provided, that if after the consummation
of such acquisition by the Company such person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person, a Change in Control of the
Company shall then occur. For purposes of this Change in Control definition, “corporation” shall include any limited liability company, partnership, association, business trust and similar organization, “board of directors” shall
refer to the ultimate governing body of such organization and “director” shall refer to any member of such governing body. 

2.7    “Code” means the Internal Revenue Code of 1986, as amended. 

2.8    “Committee” means the Compensation Committee of the Board formed to act on
performance-based compensation for Key Employees, or any successor committee or subcommittee of the Board. However, if a member of the Compensation Committee is not an “outside director” within the meaning of Section 162(m) of the
Code or is not a “non-employee director” within the meaning of Rule 16b-3 under the Exchange Act, the Compensation Committee may from time to time delegate
some or all of its functions under the Plan to a committee or subcommittee composed of members that meet the relevant requirements. The term “Committee” includes any such committee or subcommittee, to the extent of the Compensation
Committee’s delegation. 
 2.9    “Common Stock” means common stock of the
Company, par value $0.001 per share. 
 2.10    “Company” means Broadcom Inc. 

2.11    “Consultant” means any consultant or adviser engaged to provide services to
the Company or any Related Company that qualifies as a consultant under the applicable rules of the Securities and Exchange Commission for registration of shares on a Form S-8 Registration Statement. 

  
 3 

 2.12    “Disabled” or
“Disability” means permanently and totally disabled within the meaning of the Company’s Long Term Disability Plan. 

2.13    “Employee” means any individual who performs services as a common law
employee for the Company or a Related Company. “Employee” shall not include any seasonal or temporary employees. 

2.14    “Exercise Price” means the price per Share, as fixed by the Committee, at
which Shares may be purchased under a Stock Option. In no event shall the Exercise Price with respect to any Share subject to a Stock Option be set at a price that is less than the Fair Market Value of a Share as of the date of grant. 

2.15    “Fair Market Value” of a Share means either (a) the closing sales price
of a Share as listed on the NASDAQ Stock Market on the applicable date, (b) if no sales of Shares are reported for such date, for the next preceding day for which such sales were reported or (c) the fair market value of a Share determined
in accordance with any other reasonable method approved by the Committee in its discretion. 

2.16    “Fair Market Value Stock Option” means a Stock Option the Exercise Price of
which is set by the Committee at a price per Share equal to the Fair Market Value of a Share on the date of grant. 

2.17    “GAAP” means generally accepted accounting principles. 

2.18    “Good Reason” means, solely for those Participants who, on the date of grant
of an Award, (i) have an employment agreement with the CA, Inc. or the Company which defines “Good Reason”, or (ii) participate in the CIC Severance Policy, the meaning ascribed to such term in the applicable employment agreement
or CIC Severance Policy on the date of grant of the Award, except that, for the avoidance of doubt, with respect to Michael Gregoire, the definition of “Good Reason” under the Employment Agreement between CA, Inc. and Michael Gregoire,
dated December 10, 2012, shall control. 
 2.19    “Incentive Stock Option”
means a Stock Option granted under Section 4.7 of the Plan that meets the requirements of Section 422 of the Code and any regulations or rules promulgated thereunder and is designated in the Award Agreement to be an Incentive Stock
Option. 
 2.20    “Key Employee” means an Employee who is a “covered
employee” within the meaning of Section 162(m)(3) of the Code. 
 2.21    “Long-Term
Performance Bonus” means an Award described in Section 4.5 of the Plan. 

2.22    “Nonqualified Stock Option” means any Stock Option granted under
Section 4.7 of the Plan that is not an Incentive Stock Option. 

2.23    “Participant” means an Employee or Consultant who has been granted an Award
under the Plan. 
 2.24    “Performance Cycle” means a period measured by the
Company’s fiscal year or years over which the level of attainment of performance of one or more Performance Measures shall be determined; provided, however, that the Committee, in its discretion, may determine to use a period that is less than
a full fiscal year. 
 2.25    “Performance Measure” means, with respect to any
Award granted in connection with a Performance Cycle, the business criteria selected by the Committee to measure the level of performance 

  
 4 

 
of the Company during such Performance Cycle. The Committee may select as the Performance Measure for a Performance Cycle any one or combination of the following Company measures (including any
component thereof), as interpreted by the Committee, which (to the extent applicable) shall be determined on a GAAP basis, either pre-tax or after-tax and may be
determined on a per share basis: 
 (a)    Net Operating Profit; 

(b)    Return On Invested Capital; 

(c)    Total Shareholder Return; 

(d)    Relative Total Shareholder Return (as compared against a peer group of the Company, which, unless otherwise
specified by the Committee, shall be the companies comprising the Standard & Poor’s Systems Software Index, excluding the Company); 

(e)    Earnings; 

(f)    Net Income, as adjusted; 

(g)    Cash Flow; 

(h)    Revenue 

(i)    Revenue Growth; 

(j)    Share Performance; 

(k)    Relative Share Performance; 

(l)    Billings Growth; 

(m)    Customer Satisfaction; and/or 

(n)    New License Sales. 

2.26    “Plan” means the CA, Inc. 2011 Incentive Plan, as amended and restated, as
set forth in this document and as may be further amended from time to time. 
 2.27    “Qualified
Performance Award” means an Annual Performance Bonus, Long-Term Performance Bonus, Restricted Stock Award or Other Equity-Based Award that is intended by the Committee to meet the requirements for “qualified
performance-based compensation” within the meaning of Code section 162(m) and Treasury Regulation section 1.162-27(e). 

2.28    “Qualified Performance Award Determination Period” means the period within
which Committee determinations regarding Performance Measures, targets and payout formulas in connection with Qualified Performance Awards must be made. The Qualified Performance Award Determination Period is the period beginning on the first day of
a Performance Cycle and ending no later than ninety (90) days after commencement of the Performance Cycle; provided, however, that in the case of a Performance Cycle that is less than 12 months in duration, the Qualified Performance Award
Determination Period shall end no later than the date on which 25% of the Performance Cycle has elapsed. 

  
 5 

 2.29    “Related Company” means a
consolidated subsidiary of the Company for purposes of reporting in the Company’s consolidated financial statements. 

2.30    “Reporting Person” means an Employee who is subject to the reporting
requirements of Section 16(a) of the Securities Exchange Act of 1934. 
 2.31    “Restricted
Stock” means Shares issued under a Long-Term Performance Bonus under Section 4.5 or under a Restricted Stock Award pursuant to Section 4.6, which are subject to such restrictions as the Committee, in its discretion, may
impose. 
 2.32    “Retirement” means retirement (i) at or after age 55 with
ten years of service or (ii) at or after age 65. 
 2.33     “Shares” means
shares of Common Stock. 
 2.34    “Stock Option” means a right granted under
Section 4.7 of the Plan to purchase from the Company a stated number of Shares at a specified price. Stock Options awarded under the Plan shall be in the form of either Incentive Stock Options or Nonqualified Stock Options. 

2.35    “Termination of Consultancy” means the date of cessation of a
Consultant’s service relationship with the Company for any reason, with or without cause, as determined by the Company; provided, however, that a Consultant’s service relationship for purposes of the Plan will be treated as continuing
intact if there is a simultaneous establishment of an employment relationship or continuing employment relationship between Participant and the Company or a Related Company. 

2.36    “Termination of Employment” means the date of cessation of an
Employee’s employment relationship with the Company and any Related Company for any reason, with or without Cause, as determined by the Company; provided, however, that, subject to the requirements of applicable law, an Employee’s
employment relationship for purposes of the Plan will be treated as continuing if there is a simultaneous establishment of a consulting relationship or continuing consulting relationship between Participant and the Company or a Related Company and
may be treated as continuing intact while the Employee is on military leave, sick leave or other bona fide leave of absence (such as temporary employment with the Government). Notwithstanding the foregoing, for purposes of Incentive Stock Options
granted under the Plan, an Employee’s employment relationship shall be treated as continuing intact if the period of such leave does not exceed ninety (90) days, or if longer, so long as the Employee’s right to reemployment with the
Company or a Related Company is guaranteed either by statute or by contract. The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of Employment, including, but not by way of
limitation, the question of whether a particular leave of absence constitutes a Termination of Employment. 
 ARTICLE III. 

ADMINISTRATION 

3.1    The Committee. The Plan shall be administered by the Committee. 

3.2    Authority of the Committee. The Committee shall have authority, in its sole and absolute
discretion and subject to the terms of the Plan, to (1) interpret the Plan; (2) prescribe such rules and regulations as it deems necessary for the proper operation and administration of the Plan, and amend or rescind any existing rules or
regulations relating to the Plan; (3) select Employees and Consultants to receive Awards under the Plan; (4) determine the form of an Award, the number of Shares subject to an 

  
 6 

 
Award, all the terms, conditions, restrictions and/or limitations, if any, of an Award including, without limitation, the timing or conditions of exercise or vesting, and the terms of any Award
Agreement; (5) determine whether Awards will be granted singly, in combination or in tandem; (6) establish and administer Performance Measures in connection with Awards, including Qualified Performance Awards granted under the Plan;
(7) certify the level of performance attainment for Performance Measures in connection with Qualified Performance Awards granted under the Plan; (8) except as provided in Section 4.10, waive or amend any terms, conditions,
restrictions or limitations of an Award; (9) in accordance with Article V, make such adjustments to the Plan (including but not limited to adjustment of the number of shares available under the Plan or any Award) and/or to any Award granted
under the Plan, as may be appropriate; (10) accelerate the vesting, exercise or payment of an Award; (11) provide for the deferred payment of Awards in Shares and the extent to which dividend equivalents shall be paid or credited with
respect to such Awards; (12) determine whether Nonqualified Stock Options may be transferable to family members, a family trust or a family partnership; (13) establish such subplans as the Committee may determine to be necessary in order
to implement and administer the Plan in foreign countries; and (14) take any and all other action it deems necessary or advisable for the proper operation or administration of the Plan. 

3.3    Effect of Determinations. All determinations of the Committee shall be final, binding and
conclusive on all persons having an interest in the Plan. 
 3.4    Delegation of Authority. The
Committee, in its discretion, may delegate its authority and duties under the Plan to such other individual, individuals or committee as it may deem advisable, under such conditions and subject to such limitations as the Committee may establish.
Notwithstanding the foregoing, only the Committee shall have authority to grant and administer Awards to Key Employees and other Reporting Persons, to establish and certify Performance Measures and to grant Awards to any Employee who is acting as a
delegate of the Committee in respect of the Plan. 
 3.5    No Liability. No member of the
Committee, nor any person acting as a delegate of the Committee in respect of the Plan, shall be liable for any losses incurred by any person resulting from any action, interpretation or construction made in good faith with respect to the Plan or
any Award granted thereunder. 
 ARTICLE IV. 

AWARDS 

4.1    Eligibility. Except as otherwise provided herein with respect to a specific form of an Award,
all Employees and Consultants shall be eligible to receive Awards granted under the Plan. 

4.2    Participation. The Committee, at its sole discretion, shall select from time to time
Participants from those persons eligible under Section 4.1 above to receive Awards under the Plan. 

4.3    Form of Awards. (a) Awards granted under the Plan shall be in the form of Annual
Performance Bonuses, Long-Term Performance Bonuses, Restricted Stock, Stock Options, and Other Equity-Based Awards. Awards shall be in the form determined by the Committee, in its discretion, and shall be evidenced by an Award Agreement. Awards may
be granted singly, in combination or in tandem with other Awards. The terms and conditions applicable to Annual Performance Bonuses shall be as set forth in Section 4.4. The terms applicable to Long-Term Performance Bonuses shall be as set
forth in Section 4.5. The terms and conditions applicable to Restricted Stock shall be as set forth in Section 4.6. The terms and conditions applicable to Stock Options shall be as set forth in Section 4.7. The terms and conditions
applicable to Other Equity-Based Awards shall be as set forth in Section 4.8. 

  
 7 

 (b)    Qualified Performance Awards. The Committee
shall designate whether an Annual Performance Bonus, Long-Term Performance Bonus, Restricted Stock Award or Other Equity-Based Award granted under the Plan is intended to constitute a Qualified Performance Award. Qualified Performance Awards under
the Plan may be granted either separately, at the same time as other Awards designated as Qualified Performance Award, or at the same time as Awards that are not designated as Qualified Performance Awards; provided, however, that in no event may the
payment of an Award that is not a Qualified Performance Award be contingent upon the failure to attain a specific level of performance on the Performance Measure(s) applicable to a Qualified Performance Award for the same Performance Cycle. In the
event the Committee designates an Award as a Qualified Performance Award, any determinations of the Committee pertaining to Performance Measures and other terms and conditions of such Qualified Performance Award (other than a determination under
Section 4.4(c)(ii), 4.5(c)(ii) or 4.6(b)(iii) to reduce the amount of an Award) shall be in writing and made within the Qualified Performance Award Determination Period. 

4.4    Annual Performance Bonuses. The Committee may grant Annual Performance Bonuses under the Plan
only to such Employees as the Committee may from time to time select, in such amounts and subject to such terms and conditions as the Committee, in its discretion, may determine. An Annual Performance Bonus awarded under the Plan may, at the
discretion of the Committee, be designated as a Qualified Performance Award. An Annual Performance Bonus that the Committee designates as a Qualified Performance Award shall be subject to the provisions of paragraphs (a) through (d) below. 

(a)    Performance Cycles. Annual Performance Bonuses designated as Qualified Performance Awards
shall be awarded in connection with a 12-month Performance Cycle, which shall be the fiscal year of the Company; provided, however, that the Committee may, in its discretion, establish a Performance Cycle of
less than 12 months. 
 (b)    Bonus Participants. Within the Qualified Performance Award
Determination Period, the Committee shall determine the Employees who shall be eligible to receive an Annual Performance Bonus designated as a Qualified Performance Award for such Performance Cycle. 

(c)    Performance Measures; Targets; Payout Formula. 

(i)    For each Annual Performance Bonus designated as a Qualified Performance Award, the Committee shall fix and
establish, in writing, within the Qualified Performance Award Determination Period (A) the Performance Measure(s) that shall apply to such Annual Performance Bonus; (B) the target amount of such Annual Performance Bonus that shall be
payable to each such Employee; and (C) subject to paragraph (g) below, the payout formula for computing the actual amount of such Annual Performance Bonus that shall become payable with respect to each level of attained performance.
Towards this end, such payout formula shall, based on objective criteria, set forth for the applicable Performance Measure(s) the minimum level of performance that must be attained during the Performance Cycle before any such Annual Performance
Bonus shall become payable and the percentage (which percentage may not exceed 200%) of the target amount of such Annual Performance Bonus that shall be payable to each such Employee upon attainment of various levels of performance that equal or
exceed the minimum required level. 
 (ii)    Notwithstanding anything in this paragraph (c) to the contrary, the
Committee may, on a case by case basis and in its sole discretion, reduce, but not increase, any Annual Performance Bonus designated as a Qualified Performance Award that is payable to any Employee with respect to any given Performance Cycle,
provided, however, that no such reduction shall result in an increase in the dollar amount of any such Annual Performance Bonus payable to any Key Employee. 

  
 8 

 (d)    Payment of Bonuses; Certification. No Annual
Performance Bonus designated as a Qualified Performance Award shall be paid to a Key Employee under this Section 4.4 unless and until the Committee certifies in writing the level of attainment of the applicable Performance Measure(s) for the
applicable Performance Cycle. 
 (e)    Other Annual Performance Bonuses. Annual Performance
Bonuses that are not Qualified Performance Awards shall be based on a Performance Cycle (which may be less than 12 months) and such Performance Measures and payout formulas (which may be the same as or different than those applicable to Annual
Performance Bonuses that are designated as Qualified Performance Awards) as the Committee, in its discretion, may establish for such purposes. 

(f)    Form of Payment. Annual Performance Bonuses shall be paid in cash. 

(g)    Amount of Bonus. The maximum amount that may be paid as an Annual Performance Bonus to any one
Participant during any fiscal year of the Company shall not exceed $10,000,000. 
 4.5    Long-Term Performance
Bonuses. The Committee may grant Long-Term Performance Bonuses under the Plan only to such Employees as the Committee may from time to time select, in such amounts and subject to such terms and conditions as the Committee, in its
discretion, may determine. A Long-Term Performance Bonus awarded under the Plan may, at the discretion of the Committee, be designated as a Qualified Performance Award. A Long- Term Performance Bonus that the Committee designates as a Qualified
Performance Award shall be subject to the provisions of paragraphs (a) through (d) below. 

(a)    Performance Cycles. Long-Term Performance Bonuses designated as Qualified Performance Awards
shall be awarded in connection with a Performance Cycle, which shall be at least one fiscal year of the Company. The Committee shall determine the length of a Performance Cycle within the Qualified Performance Award Determination Period. In the
event that the Committee determines that a Performance Cycle shall be a period greater than one fiscal year, a new Long-Term Performance Bonus Award may be granted and designated as a Qualified Performance Award and a new Performance Cycle may
commence prior to the completion of the Performance Cycle associated with the prior Long-Term Performance Bonus Award. 

(b)    Bonus Participants. Within the Qualified Performance Award Determination Period, the Committee
shall determine the Employees who shall be eligible to receive a Long-Term Performance Bonus designated as a Qualified Performance Award for such Performance Cycle. 

(c)    Performance Measures; Targets; Payout Formula. 

(i)    For each Long-Term Performance Bonus designated as a Qualified Performance Award, the Committee shall fix and
establish, in writing, within the Qualified Performance Award Determination Period (A) the Performance Measure(s) that shall apply to such Performance Cycle; (B) the target amount of such Long-Term Performance Bonus that shall be payable
to each such Employee; and (C) subject to paragraph (g) below, the payout formula for computing the actual amount of such Long-Term Performance Bonus that shall become payable with respect to each level of attained performance. Towards
this end, such payout formula shall, based on objective criteria, set forth for the applicable Performance Measure(s) the minimum level of performance that must be attained during the Performance Cycle before any such Long-Term Performance Bonus
shall become payable and the percentage (which percentage may not exceed 200%) of the target amount of such Long-Term Performance Bonus that shall be payable to each such Employee upon attainment of various levels of performance that equal or exceed
the minimum required level. 

  
 9 

 (ii)    Notwithstanding anything in this paragraph (c) to the
contrary, the Committee may, on a case by case basis and in its sole discretion, reduce, but not increase, any Long-Term Performance Bonus designated as a Qualified Performance Award that is payable to any Employee with respect to any given
Performance Cycle, provided, however, that no such reduction shall result in an increase in the dollar amount of any such Long-Term Performance Bonus payable to any Key Employee. 

(d)    Payment of Bonuses; Certification. No Long-Term Performance Bonus designated as a Qualified
Performance Award shall be paid to a Key Employee under this Section 4.5 unless and until the Committee certifies in writing the level of attainment of the applicable Performance Measure(s) for the applicable Performance Cycle. 

(e)    Other Long-Term Performance Bonuses. Long-Term Performance Bonuses that are not Qualified
Performance Awards shall be based on such Performance Cycles, Performance Measures and payout formulas (which may be the same as or different than those applicable to Long Term Performance Bonuses that are designated as Qualified Performance Awards)
as the Committee, in its discretion, may establish for such purposes. 
 (f)    Form of Payment.
Long-Term Performance Bonuses may be either paid in cash or the value of the Award may be settled in Shares, Shares of Restricted Stock, Stock Options or other Awards or any combination of the foregoing in such proportions as the Committee may,
in its discretion, determine. To the extent that a Long-Term Performance Bonus is paid in Shares of Restricted Stock, and/or Stock Options, the number of Shares of Restricted Stock payable and/or the number of Stock Options granted shall be based on
the Fair Market Value of a Share on the date of grant, subject to such reasonable Restricted Stock discount factors and/or Stock Option valuation methodology as the Committee may, in its discretion, apply. Any Shares of Restricted Stock or Awards
granted in connection with a Long-Term Performance Bonus shall be subject to the provisions of Sections 4.6(e), (f) or 4.8, as applicable. Any Stock Options granted in payment of a Long-Term Performance Bonus shall be subject to the provisions of
Sections 4.7(a), (b), (c), (d), (f) and (g). 
 (g)    Amount of Bonus. Subject to
Section 4.6(f), the maximum amount that may be paid as a Long-Term Performance Bonus in the form of Restricted Stock to any one Participant during any fiscal year of the Company shall not exceed $20,000,000. 

4.6    Restricted Stock. The Committee may grant Restricted Stock under the Plan to such Employees as
the Committee may from time to time select, in such amounts and subject to such terms, conditions and restrictions as the Committee, in its discretion, may determine. A Restricted Stock Award may, at the discretion of the Committee, be designated as
a Qualified Performance Award. A Restricted Stock Award that the Committee designates as a Qualified Performance Award shall be subject to the provisions of paragraphs (a) through (c) below. 

(a)    Performance Cycles. A Restricted Stock Award designated as a Qualified Performance Award shall
be awarded in connection with a Performance Cycle. Unless the Committee determines that some other period shall apply, the Performance Cycle shall be the fiscal year of the Company. In the event that the Committee determines that a Performance Cycle
shall be a period greater than a 12-month period, a new Restricted Stock Award may be granted and designated as a Qualified Performance Award and a new Performance Cycle may commence prior to the completion of
the Performance Cycle associated with the prior Restricted Stock Award. 

  
 10 

 (b)    Performance Measures; Targets and Payout
Formulas. 
 (i)    Within the Qualified Performance Award Determination Period, the Committee shall
determine the Employees who shall be eligible to receive a Restricted Stock Award designated as a Qualified Performance Award for such Performance Cycle and shall establish, in writing, the Performance Measure(s) that shall apply for such
Performance Cycle. 
 (ii)    For each Restricted Stock Award designated as a Qualified Performance Award, the
Committee shall establish, in writing, within the Qualified Performance Award Determination Period (A) a target amount of Restricted Stock that shall be payable to each such Employee and (B) subject to paragraph (f) below, a payout
formula for computing the actual amount of Restricted Stock that shall become payable with respect to each level of attained performance. Towards this end, such payout formula shall, based on objective criteria, set forth for the applicable
Performance Measure the minimum level of performance that must be attained during the Performance Cycle before any such Restricted Stock shall become payable and the percentage (which percentage may not exceed 200%) of the target amount of
Restricted Stock that shall be payable to each such Employee upon attainment of various levels of performance that equal or exceed the minimum required level. 

(iii)    The actual amount of Restricted Stock that shall be paid to each such Employee for any given Performance Cycle
under a Restricted Stock Award designated as a Qualified Performance Award shall be determined based on such Employee’s target Restricted Stock Award, the actual level of achievement of the Performance Measure(s) and the payout formula
determined by the Committee pursuant to this paragraph (b) for such Performance Cycle. Notwithstanding the foregoing, the Committee may, on a case by case basis and in its sole discretion, reduce, but not increase, the actual amount of any
Restricted Stock Award designated as a Qualified Performance Award that is payable to any Employee with respect to any given Performance Cycle, provided, however, that no such reduction shall result in an increase in the amount of such
Restricted Stock Award payable to any Key Employee. 
 (c)    Committee Certification. No Shares of
Restricted Stock payable under a Restricted Stock Award designated as a Qualified Performance Award shall be paid to a Key Employee under this Section 4.6 unless and until the Committee certifies in writing the level of attainment of the
applicable Performance Measure(s) for the applicable Performance Cycle. 
 (d)    Other Restricted Stock
Awards. Restricted Stock Awards that are not Qualified Performance Awards shall be subject to such provisions as the Committee may, in its discretion, determine, and may be granted at any time; provided, however, that to the extent
that the Committee determines that a Restricted Stock Award that is not a Qualified Performance Award shall be performance-based, such Restricted Stock Award shall be awarded in connection with a Performance Cycle, applying such Performance Measures
and payout formulas (which may be the same as or different than those applicable to Restricted Stock Awards designated as Qualified Performance Awards) as the Committee, in its discretion, may establish for such purposes. 

(e)    Payment of Restricted Stock. As soon as practicable after Restricted Stock has been awarded, a
certificate or certificates for all such Shares of Restricted Stock shall be registered in the name of the Participant and, at the discretion of the Company, be either (i) delivered to the Participant or (ii) held for the Participant by
the Company. The Participant shall thereupon have all the rights of a stockholder with respect to such Shares, including the right to vote and receive dividends or other distributions made or paid with respect to such Shares, except that such Shares
shall be subject to the vesting and forfeiture provisions of paragraph (e)(i) below. The Committee may, in its discretion, impose such restrictions on Restricted Stock as it deems appropriate. Except as the Committee may otherwise

  
 11 

 
determine, and subject to the Committee’s authority under Section 3.2, such Shares shall be subject to the following vesting provisions: 

(i)    Vesting and Forfeiture. Shares of Restricted Stock that have not yet vested shall be
forfeited by a Participant upon the Participant’s Termination of Employment for any reason other than death or Disability. Shares of Restricted Stock shall vest in approximately equal annual installments over a three — year period after
the end of the applicable Performance Cycle (or date of grant, in the case of Awards that are not Qualified Performance Awards). 

(ii)    Acceleration of Vesting. Notwithstanding the foregoing, all Shares of Restricted Stock shall
immediately vest upon the death or Disability of the Participant. 
 (iii)    Legend. In order to
enforce any restrictions that the Committee may impose on Restricted Stock, the Committee shall cause a legend or legends setting forth a specific reference to such restrictions to be placed on all certificates for Shares of Restricted Stock. As
restrictions are released, a new certificate, without the legend, for the number of Shares with respect to which restrictions have been released shall be issued and delivered to the Participant as soon as possible thereafter. 

(f)    Amount of Restricted Stock. The maximum aggregate number of Shares of Restricted Stock that
may be issued to any one Participant under Section 4.5 and this Section 4.6 during any fiscal year of the Company shall not exceed 201,000 Shares, subject to adjustment as provided in Section 5.3. 

4.7    Stock Options. Stock Options granted under the Plan may, at the discretion of the Committee,
be in the form of either Nonqualified Stock Options, Incentive Stock Options or a combination of the two, subject to the restrictions set forth in paragraph (e) below. Where both a Nonqualified Stock Option and an Incentive Stock Option are
granted to a Participant at the same time, such Awards shall be deemed to have been granted in separate grants, shall be clearly identified, and in no event will the exercise of one such Award affect the right to exercise the other Award. Unless
otherwise specified, a Stock Option shall be a Non-Qualified Stock Option. Except as the Committee may otherwise determine, and subject to the Committee’s authority under Section 3.2, Stock Options
shall be subject to the following terms and conditions: 
 (a)    Amount of Shares. The Committee
may grant Stock Options to a Participant in such amounts as the Committee may determine, subject to the limitations set forth in Section 5.1 of the Plan. The number of Shares subject to a Stock Option shall be set forth in the applicable Award
Agreement. 
 (b)    Exercise Price. Stock Options granted under the Plan shall be Fair Market
Value Stock Options. The Exercise Price of a Stock Option, as determined by the Committee pursuant to this Section 4.7(b), shall be set forth in the applicable Award Agreement. 

(c)    Option Term. Except as provided in Section 4.7(g), all Stock Options granted under the
Plan shall lapse no later than the tenth anniversary of the date of grant. 
 (d)    Timing of
Exercise. Except as may otherwise be provided in the Award Agreement or as the Committee may otherwise determine, and subject to the Committee’s authority under Section 3.2 to accelerate the vesting of an Award and to waive
or amend any terms, conditions, 

  
 12 

 
limitations or restrictions of an Award, each Stock Option granted under the Plan shall be exercisable in whole or in part, subject to the following conditions, limitations and restrictions: 

(i)    34% of the Shares subject to a Stock Option shall first become exercisable on the
one-year anniversary of the date of grant, 33% shall first become exercisable on the two-year anniversary of the date of grant and the remainder shall first become
exercisable on the three-year anniversary of the date of grant; 
 (ii)    All Stock Options granted to a Participant
shall become immediately exercisable upon the death or Disability of the Participant and must be exercised, if at all, within one year after such Participant’s death or Disability, but in no event after the date such Stock Options would
otherwise lapse. Stock Options of a deceased Participant may be exercised only by the estate of the Participant or by the person given authority to exercise such Stock Options by the Participant’s will or by operation of law. In the event a
Stock Option is exercised by the executor or administrator of a deceased Participant, or by the person or persons to whom the Stock Option has been transferred by the Participant’s will or the applicable laws of descent and distribution, the
Company shall be under no obligation to deliver Shares thereunder unless and until the Company is satisfied that the person or persons exercising the Stock Option is or are the duly appointed executor(s) or administrator(s) of the deceased
Participant or the person to whom the Stock Option has been transferred by the Participant’s will or by the applicable laws of descent and distribution; 

(iii)    Upon an Employee’s Retirement, all Stock Options that have not become exercisable as of the date of
Retirement shall be forfeited and to the extent that Stock Options have become exercisable as of such date, such Stock Options must be exercised, if at all, within one year after Retirement, but in no event after the date such Stock Options would
otherwise lapse; and 
 (iv)    Except as otherwise provided in Section 4.7(g) or Section 7.5, upon an
Employee’s Termination of Employment, or a Consultant’s Termination of Consultancy, for any reason other than death, Disability or Retirement, all Stock Options that have not become exercisable as of the date of termination shall be
forfeited and to the extent that Stock Options have become exercisable as of such date, such Stock Options must be exercised, if at all, within 90 days after such Termination of Employment or Termination of Consultancy. 

(e)    Payment of Exercise Price. The Exercise Price shall be paid in full when the Stock Option is
exercised and stock certificates shall be registered and delivered only upon receipt of such payment. Unless otherwise provided by the Committee, payment of the Exercise Price may be made in cash or by certified check, bank draft, wire transfer, or
postal or express money order or any other form of consideration approved by the Committee. In addition, at the discretion of the Committee, payment of all or a portion of the Exercise Price may be made by 

(i)    Delivering a properly executed exercise notice to the Company, or its agent, together with irrevocable
instructions to a broker to deliver promptly to the Company the amount of sale proceeds with respect to the portion of the Shares to be acquired upon exercise having a Fair Market Value on the date of exercise equal to the sum of the applicable
portion of the Exercise Price being so paid and appropriate tax withholding; 
 (ii)    Tendering (actually or by
attestation) to the Company previously acquired Shares that have been held by the Participant for at least six months having a Fair Market Value on the day prior to the date of exercise equal to the applicable portion of the Exercise Price being so
paid; or 
 (iii)    any combination of the foregoing. 

  
 13 

 (f)    Incentive Stock Options. Incentive Stock
Options granted under the Plan shall be subject to the following additional conditions, limitations and restrictions: 

(i)    Eligibility. Incentive Stock Options may only be granted to Employees of the Company or a
Related Company that is a subsidiary or parent corporation, within the meaning of Code Section 424, of the Company (an “ISO Related Company”). In no event may an Incentive Stock Option be granted to an Employee who owns stock
possessing more than 10% of the total combined voting power of all classes of stock of the Company or such Related Company or to a Consultant. 

(ii)    Timing of Grant. No Incentive Stock Option shall be granted under the Plan after the 10-year anniversary of the date the Plan is adopted by the Board. 

(iii)    Amount of Award. The aggregate Fair Market Value on the date of grant of the Shares with
respect to which such Incentive Stock Options first become exercisable during any calendar year under the terms of the Plan for any Participant may not exceed $100,000 (or such other limit as may be specified in the Code). For purposes of this
$100,000 limit, the Participant’s Incentive Stock Options under this Plan and all Plan’s maintained by the Company and an ISO Related Company shall be aggregated. To the extent any Incentive Stock Option first becomes exercisable in a
calendar year and such limit would be exceeded, such Incentive Stock Option shall thereafter be treated as a Nonqualified Stock Option for all purposes. 

(iv)    Timing of Exercise. In the event that the Committee exercises its discretion to permit an
Incentive Stock Option to be exercised by a Participant more than 90 days after the Participant’s termination of employment with the Company and such exercise occurs more than three months after such Participant has ceased being an Employee (or
more than 12 months after the Participant is Disabled or dies), such Incentive Stock Option shall thereafter be treated as a Nonqualified Stock Option for all purposes. 

(v)    Transfer Restrictions. In no event shall the Committee permit an Incentive Stock Option to be
transferred by a Participant other than by will or the laws of descent and distribution, and any Incentive Stock Option granted hereunder shall be exercisable, during his or her lifetime, only by the Participant. 

(g)    Extension of Stock Option Term for Blackouts. At its discretion, the Committee may extend the
term of any Stock Option beyond its earlier termination pursuant to Section 4.7(c), (d)(ii), (iii) or (iv) if the Company had prohibited the participant from exercising the option prior to termination or expiration in order to comply with
applicable Federal, state, local or foreign law, provided that such extension may not exceed 30 days from the date such prohibition is lifted. 

4.8    Other Equity-Based Awards. The Committee may, from time to time, grant Awards (other than
Performance Bonuses, Restricted Stock or Stock Options) under this Section 4.8 that consist of, or are denominated in, payable in, valued in whole or in part by reference to, or otherwise based on or related to, Shares to any Employee or
Consultant. These Awards may include, among other things Shares, restricted stock options, restricted stock units, stock appreciation rights (SARs) (which shall lapse no later than the tenth anniversary of the grant date, subject to extension
consistent with Section 4.7(g)), phantom or hypothetical Shares and Share units. The Committee shall determine, in its discretion, the terms, conditions, restrictions and limitations, if any, that shall apply to Awards granted pursuant to this
Section 4.8, including whether dividend equivalents shall be credited or paid with respect to any Award, which terms, conditions, restrictions and/or limitations shall be set forth in the applicable Award Agreement; provided, however, that in
no event will the exercise price of an SAR with respect to any Share be less than the Fair Market Value of a Share as of the date of grant. 

  
 14 

 Other Equity Based Awards under the Plan may, in the discretion of the Committee, be
designated as Qualified Performance Awards. In the event the Committee designates an Other Equity-Based Award as a Qualified Performance Award, the Committee shall condition the grant of such Other Equity- Based Award on the attainment during a
Performance Cycle of specified levels of performance of one or more Performance Measures. The Performance Cycle, Performance Measure(s) and payout schedules applicable to Other Equity-Based Awards that are designated as Qualified Performance Awards
shall be determined by the Committee at such time and in the manner as set out in paragraphs (a) and (b) of Section 4.6. In such case, no Other Equity-Based Award designated as a Qualified Performance Award shall be paid to a Key Employee
under this Section 4.8 unless and until the Committee certifies in writing the level of attainment of the applicable Performance Measure(s) for the applicable Performance Cycle. 

4.9    Code Section 162(m). It is the intent of the Company that
Qualified Performance Awards granted to Key Employees under the Plan satisfy the applicable requirements of Code Section 162(m) and the regulations thereunder so that the Company’s tax deduction for Qualified Performance Awards is not
disallowed in whole or in part by operation of Code Section 162(m). If any provision of this Plan pertaining to Qualified Performance Awards, or any Award to a Key Employee under the Plan that the Committee designates as a Qualified Performance
Award, would otherwise frustrate or conflict with such intent, that provision or Award shall be interpreted and deemed amended so as to avoid such conflict. 

4.10    No Repricing. Repricing of Options or SARs shall not be permitted without stockholder
approval. For this purpose, a “repricing” means any of the following (or any other action that has the same effect as any of the following): (A) changing the terms of an Option or SAR to lower its Exercise Price (other than pursuant to
Section 5.3); (B) any other action that is treated as a “repricing” under generally accepted accounting principles; and (C) repurchasing for cash or canceling an Option or SAR at a time when its Exercise Price is greater than the
Fair Market Value of the underlying stock in exchange for another Award, unless the cancellation and exchange occurs in connection with an event set forth in Section 5.3. Such cancellation and exchange would be considered a
“repricing” regardless of whether it is treated as a “repricing” under generally accepted accounting principles and regardless of whether it is voluntary on the part of the Participant. 

4.11    Change in Control. Subject to the last sentence of this paragraph, (a) except as
otherwise determined by the Committee, if the Committee determines that, in connection with a Change in Control, (x) the Common Stock of the Company (or of any direct or indirect parent entity) will not be publicly traded or (y) any Award
will not be honored or assumed, or new rights that substantially preserve the terms of such Award substituted therefor, any outstanding Award then held by a Participant which is unexercisable or otherwise unvested or subject to lapse restrictions
will automatically be deemed exercisable or otherwise vested or no longer subject to lapse restrictions, as the case may be, as of the date of such Change in Control or (b) if the Committee determines that, in connection with a Change in
Control, (x) the Common Stock of the Company or of any direct or indirect parent entity will be publicly traded and (y) any Award will be honored or assumed, or new rights that substantially preserve the terms of such Award substituted
therefore, if a Participant’s employment is terminated without Cause, or, solely for Participants who have an employment agreement with the Company which defines “Good Reason” or who participate in the CIC Severance Policy immediately
prior to the Merger Effective Time, for Good Reason, within a 2-year period following such Change in Control, any outstanding Award then held by such Participant which is unexercisable or otherwise unvested or
subject to lapse restrictions will automatically be deemed exercisable or otherwise vested or no longer subject to lapse restrictions, as the case may be, as of the date such Participant’s employment is terminated. Notwithstanding anything
herein to the contrary, this Section 4.11 shall not apply to (i) any Award that is an Annual Performance Bonus, whenever granted and (ii) any other Award granted on or after the Merger Agreement Signing Date. 

  
 15 

 ARTICLE V. 

SHARES SUBJECT TO THE PLAN; ADJUSTMENTS 

5.1    Shares Available. The Shares issuable under the Plan shall be authorized but unissued Shares
or Shares held in the Company’s treasury. Subject to adjustments in accordance with Section 5.3, the total number of Shares with respect to which Awards may be issued during the term of the Plan may equal but shall not exceed in the
aggregate 9,064,975 Shares, which includes 3,034,975 shares available for grant under the 2007 Plan, as of June 6, 2011. Of the shares available under the Plan no more than 2,010,000 Shares may be granted in the form of Incentive Stock Options
and the maximum aggregate number of Shares with respect to which Awards may be granted to any one Participant during any such fiscal year of the Company may not exceed 603,000 Shares. Any Shares (a) delivered by the Company, (b) with
respect to which Awards are made hereunder and (c) with respect to which the Company becomes obligated to make Awards, in each case through the assumption of, or in substitution for, outstanding awards previously granted by an acquired entity,
shall not count against the Shares available to be delivered pursuant to Awards under this Plan. 

5.2    Counting Rules. For purposes of determining the number of Shares remaining available under the
Plan, only Awards payable in Shares shall be counted. Any Shares related to Awards under the Plan, which terminate by expiration, forfeiture, cancellation or otherwise without issuance of Shares, or are settled in cash in lieu of Shares, shall be
available again for issuance under the Plan. In the event Shares are tendered or withheld in payment of all or part of the Exercise Price of a Stock Option, or in satisfaction of the withholding obligations of any Award, the Shares so tendered or
withheld shall become available for issuance under the Plan. To the extent that any option or other award outstanding pursuant to the 2007 Plan as of the Effective Date which for any reason, on or after the Effective Date, expires, is terminated,
forfeited or cancelled without having been exercised or settled in full, Shares subject to such awards shall deem to have not been delivered and shall be added to the share maximum; provided, however, that the aggregate number of Shares outstanding
under the 2007 Plan that may be added to the share maximum pursuant to this Section 5.2 shall not exceed 2,167,997 shares, the number of shares subject to outstanding awards under the 2007 Plan as of June 6, 2011 (as such number may be
adjusted from time to time as provided in Section 5.3). With respect to stock appreciation rights (“SARs”), when a SAR is exercised and settled in whole or in part in Shares, the Shares subject to a SAR grant agreement shall be
counted against the Shares available for issuance as one (1) Share for every Share subject thereto, regardless of the number of Shares used to settle the SAR upon exercise. 

5.3    Adjustments. In the event of any change in the number of issued Shares (or issuance of shares
of stock other than shares of Common Stock) by reason of any stock split, reverse stock split, or stock dividend, recapitalization, reclassification, merger, consolidation, split-up, spin-off, reorganization, combination, or exchange of Shares, , the issuance of warrants or other rights to purchase Shares or other securities, or any other change in corporate structure or in the event of any
extraordinary distribution (whether in the form of cash, Shares, other securities or other property), the Committee shall adjust the number or kind of Shares that may be issued under the Plan, and the terms of any outstanding Award (including,
without limitation, the number of Shares subject to an outstanding Award, the type of property to which the Award relates and the Exercise Price of a Stock Option, stock appreciation right or other Award) in such manner as the Committee shall
determine is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, and such adjustment shall be conclusive and binding for all purposes under the Plan.
Notwithstanding the foregoing, no adjustments shall be made with respect to Qualified Performance Awards granted to a Key Employee to the extent such adjustment would cause the Award to fail to qualify as performance-based compensation under
Section 162(m) of the Code and no adjustment shall be required if the Committee determines that such action could cause an Award to fail to satisfy the conditions of an applicable exception from the requirements of Section 409A of the Code
(“Section 409A”) or otherwise could subject a Participant to the additional tax imposed under Section 409A in respect of an outstanding Award. 

  
 16 

 5.4    Consolidation, Merger or Sale of Assets.
Upon the occurrence of (i) a merger, consolidation, acquisition of property or stock, reorganization or otherwise involving the Company in which the Company is not to be the surviving corporation, (ii) a merger, consolidation,
acquisition of property or stock, reorganization or otherwise involving the Company in which the Company is the surviving corporation but holders of Shares receive securities of another corporation, or (iii) a sale of all or substantially all
of the Company’s assets (as an entirety) or capital stock to another person, any Award granted hereunder shall be deemed to apply to the securities, cash or other property (subject to adjustment by cash payment in lieu of fractional interests)
to which a holder of the number of Shares equal to the number of Shares the Participant would have been entitled, and proper provisions shall be made to ensure that this clause is a condition to any such transaction; provided, however,
that the Committee (or, if applicable, the board of directors of the entity assuming the Company’s obligations under the Plan) shall, in its discretion, have the power to either: 

(a)    provide, upon written notice to Participants, that all Awards that are currently exercisable must be exercised
within the time period specified in the notice and that all Awards not exercised as of the expiration of such period shall be terminated without consideration; provided, however, that the Committee (or successor board of directors) may
provide, in its discretion, that, for purposes of this subsection, all outstanding Awards are currently exercisable, whether or not vested; or 

(b)    cancel any or all Awards and, in consideration of such cancellation, pay to each Participant an amount in cash with
respect to each Share issuable under an Award equal to the difference between the Fair Market Value of such Share on such date (or, if greater, the value per Share of the consideration received by holders of Shares as a result of such merger,
consolidation, reorganization or sale) and the Exercise Price. 
 5.5    Fractional Shares. No
fractional Shares shall be issued under the Plan. In the event that a Participant acquires the right to receive a fractional Share under the Plan, such Participant shall receive, in lieu of such fractional Share, cash equal to the Fair Market Value
of the fractional Share as of the date of settlement. 
 ARTICLE VI. 

AMENDMENT AND TERMINATION 

6.1    Amendment. The Plan may be amended at any time and from time to time by the Board without the
approval of shareholders of the Company, except that no amendment which increases the aggregate number of Shares which may be issued pursuant to the Plan, decreases the Exercise Price at which Stock Options or stock appreciation rights may be
granted or materially modifies the eligibility requirements for participation in the Plan shall be effective unless and until the same is approved by the shareholders of the Company. No amendment of the Plan shall materially adversely affect any
right of any Participant with respect to any Award theretofore granted without such Participant’s written consent. 

6.2    Termination. The Plan shall terminate upon the earlier of the following dates or events to
occur: 
 (a)    the adoption of a resolution of the Board terminating the Plan; or 

  
 17 

 (b)    the 10-year anniversary
of the date of CA, Inc.’s 2011 Annual Meeting of Stockholders 
 No Awards shall be granted under this Plan after it has been
terminated. However, the termination of the Plan shall not alter or impair any of the rights or obligations of any person, without such person’s consent, under any Award theretofore granted under the Plan. After the termination of the Plan, any
previously granted Awards shall remain in effect and shall continue to be governed by the terms of the Plan and the applicable Award Agreement. 

ARTICLE VII. 
 GENERAL
PROVISIONS 
 7.1    Nontransferability of Awards. Except as otherwise provided in this
Section 7.1, no Awards under the Plan shall be subject in any manner to alienation, anticipation, sale, assignment, pledge, encumbrance or transfer, other than by will or by the laws of descent or distribution, by the Participant and no other
persons shall otherwise acquire any rights therein. During the lifetime of a Participant, Stock Options (except for Nonqualified Stock Options that are transferable pursuant to subparagraphs (a) and (b) below) shall be exercisable only by the
Participant and shall not be assignable or transferable except as provided above. 
 (a)    In the case of a
Nonqualified Stock Option, except as the Committee may otherwise determine, and subject to the Committee’s authority under Section 3.2 to waive or amend any terms, conditions, limitations or restrictions of an Award, all or any part of
such Nonqualified Stock Option may, subject to the prior written consent of the Committee, be transferred to one or more of a following classes of donees: family member, a trust for the benefit of a family member, a limited partnership whose
partners are solely family members or any other legal entity set up for the benefit of family members. For purposes of this Section 7.1, a family member means a Participant’s spouse, children, grandchildren, parents, grandparents (natural,
step, adopted, or in-laws), siblings, nieces, nephews and grandnieces and grandnephews. 

(b)    Except as the Committee may at any time determine, and subject to the Committee’s authority under
Section 3.2 to waive or amend any terms, conditions, limitations or restrictions of an Award, any Nonqualified Stock Option transferred by a Participant pursuant to paragraph (a) above may be exercised by the transferee only to the extent
such Nonqualified Stock Option would have been exercisable by the Participant had no transfer occurred. Any such transferred Nonqualified Stock Option shall be subject to all of the same terms and conditions as provided in the Plan and in the
applicable Award Agreement. The Participant or the Participant’s estate shall remain liable for any withholding tax which may be imposed by any federal, state or local tax authority and the transfer of Shares upon exercise of such Nonqualified
Stock Option shall be conditioned on the payment of such withholding tax. The Committee may, in its sole discretion, withhold its consent to all or a part of any transfer of a Nonqualified Stock Option pursuant to this Section 7.1 unless and
until the Participant makes arrangements satisfactory to the Committee for the payment of any such withholding tax. The Participant must immediately notify the Committee, in such form and manner as required by the Committee, of any proposed transfer
of a Nonqualified Stock Option pursuant to this Section and no such transfer shall be effective until the Committee consents thereto in writing. 

(c)    Anything in this Section 7.1 to the contrary notwithstanding, in no event may the Committee permit an
Incentive Stock Option to be transferred by any Participant other than by will or the laws of descent and distribution. 

  
 18 

 7.2    Withholding of Taxes. 

(a)    Stock Options. As a condition to the delivery of any Shares pursuant to the exercise of a Stock
Option, the Committee may require that the Participant, at the time of such exercise, pay to the Company by cash or by certified check, bank draft, wire transfer or postal or express money order an amount sufficient to satisfy any applicable tax
withholding obligations. The Committee may, however, in its discretion, accept payment of tax withholding obligations through any of the Exercise Price payment methods described in Section 4.7(e). In addition, the Committee may, in its
discretion, permit payment of tax withholding obligations to be made by instructing the Company to withhold Shares that would otherwise be issued on exercise having a Fair Market Value on the date of exercise equal to the applicable portion of the
tax withholding obligations being so paid. Notwithstanding the foregoing, in no event may any amount greater than the minimum statutory withholding obligation or such other withholding obligation as required by applicable law be satisfied by
tendering or withholding Shares. 
 (b)    Restricted Stock. Except as otherwise determined by the
Board or the Committee, the Company shall satisfy tax withholding obligations arising in connection with the release of restrictions on Shares of Restricted Stock or Restricted Stock Units held by Participants subject to the tax laws of the United
States, United Kingdom or Israel (and such other country where withholding is required at the time of the release of restrictions or as may be determined by the Company from time to time) by withholding Shares that would otherwise be available for
delivery upon such release having a Fair Market Value on the date of release equal to the minimum statutory withholding obligation or such other withholding obligation as required by applicable law. 

(c)    Awards. To the extent not covered by 7.2(a) or (b) above, as a condition to the delivery
of any Shares, other property or cash pursuant to any Award or the lifting or lapse of restrictions on any Award, or in connection with any other event that gives rise to a federal or other governmental tax withholding obligation on the part of the
Company relating to an Award (including, without limitation, FICA tax), (a) the Company may deduct or withhold (or cause to be deducted or withheld) from any payment or distribution to the Participant, whether or not pursuant to the Plan,
(b) the Company shall be entitled to require that the Participant remit cash to the Company (through payroll deduction or otherwise) or (c) the Company may enter into any other suitable arrangements to withhold, in each case in an amount
sufficient in the opinion of the Company to satisfy such withholding obligation. 
 7.3    Non-Uniform Determinations. None of Committee’s determinations under the Plan and Award Agreements need to be uniform and any such determinations may be made by it selectively among persons who
receive, or are eligible to receive, Awards under the Plan (whether or not such persons are similarly situated). Without limiting the generality of the foregoing, the Committee shall be entitled, among other things, to make non-uniform and selective determinations under Award Agreements, and to enter into non-uniform and selective Award Agreements, as to (a) the persons to receive Awards,
(b) the terms and provisions of Awards, (c) whether a Participant’s employment has been terminated for purposes of the Plan and (d) any adjustments to be made to Awards pursuant to Section 5.3 or otherwise. 

7.4    Required Consents and Legend. (a) If the Committee shall at any time determine that any
consent (as hereinafter defined) is necessary or desirable as a condition of, or in connection with, the granting of any Award, the delivery of Shares or the delivery of any cash, securities or other property under the Plan, or the taking of any
other action thereunder (each such action being hereinafter referred to as a “plan action”), then such plan action shall not be taken, in whole or in part, unless and until such consent shall have been effected or obtained to the full
satisfaction of the Committee. The Committee may direct that any Certificate evidencing Shares delivered pursuant to the Plan shall bear a legend setting forth such restrictions on transferability as the Committee may determine to be necessary or
desirable, and may advise the transfer agent to place a stop order against any legended shares. By accepting an Award, each Participant shall have expressly provided consent to the items described in Section 7.4(b)(iv) hereof. 

  
 19 

 (b)    The term “consent” as used herein with respect to any
plan action includes (i) any and all listings, registrations or qualifications in respect thereof upon any securities exchange or under any federal, state or local law, or law, rule or regulation of a jurisdiction outside the United States,
(ii) any and all written agreements and representations by the Participant with respect to the disposition of shares, or with respect to any other matter, which the Committee may deem necessary or desirable to comply with the terms of any such
listing, registration or qualification or to obtain an exemption from the requirement that any such listing, qualification or registration be made, (iii) any and all other consents, clearances and approvals in respect of a plan action by any
governmental or other regulatory body or any stock exchange or self-regulatory agency, (iv) any and all consents by the Participant to (A) the Company’s supplying to any third party recordkeeper of the Plan such personal information
as the Committee deems advisable to administer the Plan, (B) the Company’s deducting amounts from the Participant’s wages, or another arrangement satisfactory to the Committee, to reimburse the Company for advances made on the
Participant’s behalf to satisfy certain withholding and other tax obligations in connection with an Award and (C) the Company’s imposing sales and transfer procedures and restrictions and hedging restrictions on Shares delivered under
the Plan and (v) any and all consents or authorizations required to comply with, or required to be obtained under, applicable local law or otherwise required by the Committee. Nothing herein shall require the Company to list, register or
qualify the Shares on any securities exchange. 
 7.5    Special Forfeiture Provision. If the
Committee, in its discretion, determines and the applicable Award Agreement so provides, a Participant who, without prior written approval of the Company, enters into any employment or consultation arrangement (including service as an agent,
partner, stockholder, consultant, officer or director) to any entity or person engaged in any business in which the Company or its affiliates is engaged which, in the sole judgment of the Company, is competitive with the Company or any subsidiary or
affiliate, (i) shall forfeit all rights under any outstanding Stock Option or stock appreciation right and shall return to the Company the amount of any profit realized upon the exercise, within such period as the Committee may determine, of
any Stock Option or stock appreciation right and (ii) shall forfeit and return to the Company all Shares of Restricted Stock and other Awards which are not then vested or which vested but remain subject to the restrictions imposed by this
Section 7.3, as provided in the Award Agreement. 
 7.6    Code
Section 83(b) Elections. Neither the Company, any Related Company, nor the Committee shall have any responsibility in connection with a Participant’s election, or attempt to elect, under Code
section 83(b) to include the value of a Restricted Stock Award in the Participant’s gross income for the year of payment. Any Participant who makes a Code section 83(b) election with respect to any such Award shall promptly notify the Committee
of such election and provide the Committee with a copy thereof. 
 7.7    No Implied Rights. The
establishment and subsequent operation of the Plan, including eligibility as a Participant, shall not be construed as conferring any legal or other right upon any Employee for the continuation of his or her employment, or upon any Consultant for the
continuation of his or her consultancy, for any Performance Cycle or any other period. The Company expressly reserves the right, which may be exercised at any time and without regard to when, during a Performance Cycle or other accounting period,
such exercise occurs, to discharge any individual and/or treat him or her without regard to the effect which such treatment might have upon him or her under any outstanding Award. 

7.8    No Obligation to Exercise Options. The granting of a Stock Option shall impose no obligation
upon the Participant to exercise such Stock Option. 

  
 20 

 7.9    No Rights as Stockholders. A Participant
granted an Award under the Plan shall have no rights as a stockholder of the Company with respect to such Award unless and until such time as certificates for the Shares underlying the Award are registered in such Participant’s name. The right
of any Participant to receive Shares by virtue of the terms of an Award or participation in the Plan shall be no greater than the right of any unsecured general creditor of the Company. With respect to any or all Awards, the Company may, in lieu of
physical certificates, cause for electronic shares to be held in the Participant’s name with a transfer agent or broker. 

7.10    Indemnification of Committee. The Company shall indemnify, to the full extent permitted by
law, each person made or threatened to be made a party to any civil or criminal action or proceeding by reason of the fact that he, or his testator or intestate, is or was a member of the Committee or a delegate of the Committee so acting. 

7.11    No Required Segregation of Assets. Neither the Company nor any Related Company shall be
required to segregate any assets that may at any time be represented by Awards granted pursuant to the Plan. 

7.12    Nature of Payments. All Awards made pursuant to the Plan are in consideration of services for
the Company or the Related Companies. Any gain realized pursuant to Awards under the Plan constitutes a special incentive payment to the Participant and shall not be taken into account as compensation for purposes of any of the employee benefit
plans of the Company or any Related Company except as may be determined by the Board or by the board of directors of the applicable Related Company. 

7.13    Securities Exchange Act Compliance. Awards under the Plan are intended to satisfy the
requirements of Rule 16b-3 under the Securities Exchange Act of 1934. If any provision or this Plan or of any grant of an Award would otherwise frustrate or conflict with such intent, that provision shall be
interpreted and deemed amended so as to avoid such conflict. 
 7.14    Section 409A 

(a)    All Awards made under the Plan that are intended to be “deferred compensation” subject to
Section 409A shall be interpreted, administered and construed to comply with Section 409A, and all Awards made under the Plan that are intended to be exempt from Section 409A shall be interpreted, administered and construed to comply
with and preserve such exemption. The Committee shall have full authority to give effect to the intent of the foregoing sentence. To the extent necessary to give effect to this intent, in the case of any conflict or potential inconsistency between
the Plan and a provision of any Award or Award Agreement with respect to an Award, the Plan shall govern. 

(b)    Without limiting the generality of Section 7.14(a), with respect to any Award made under the Plan that is
intended to be “deferred compensation” subject to Section 409A: (a) any payment to be made with respect to such Award in connection with the Participant’s separation from service to the Company within the meaning of
Section 409A (and any other payment that would be subject to the limitations in Section 409A(a)(2)(b) of the Code) shall be delayed until six months after the Participant’s separation from service (or earlier death) in accordance with
the requirements of Section 409A; (b) if any payment to be made with respect to such Award would occur at a time when the tax deduction with respect to such payment would be limited or eliminated by Section 162(m), such payment may be
deferred by the Company under the circumstances described in Section 409A until the earliest date that the Company reasonably anticipates that the deduction or payment will not be limited or eliminated; (c) to the extent necessary to
comply with Section 409A, any other securities, other Awards or other property that the Company may deliver in lieu of shares of Common Stock in respect of an Award 

  
 21 

 
shall not have the effect of deferring delivery or payment beyond the date on which such delivery or payment would occur with respect to the shares of Common Stock that would otherwise have been
deliverable (unless the Committee elects a later date for this purpose in accordance with the requirements of Section 409A); (d) with respect to any required consent described in Section 7.4 or the applicable Award Agreement, if such
consent has not been effected or obtained as of the latest date provided by such Award Agreement for payment in respect of such Award and further delay of payment is not permitted in accordance with the requirements of Section 409A, such Award
or portion thereof, as applicable, will be forfeited and terminate notwithstanding any prior earning or vesting; (e) if the Award includes a “series of installment payments” (within the meaning of
Section 1.409A-2(b)(2)(iii) of the Treasury Regulations), the Participant’s right to the series of installment payments shall be treated as a right to a series of separate payments and not as a right
to a single payment; (f) if the Award includes “dividend equivalents” (within the meaning of Section 1.409A-3(e) of the Treasury Regulations), the Participant’s right to the dividend
equivalents shall be treated separately from the right to other amounts under the Award; and (g) for purposes of determining whether the Participant has experienced a separation from service to the Company within the meaning of
Section 409A, “subsidiary” shall mean a corporation or other entity, starting with Broadcom Inc., in a chain of corporations or other entities in which each corporation or other entity has a controlling interest in another corporation
or other entity in the chain, ending with such corporation or other entity. For purposes of the preceding sentence, the term “controlling interest” has the same meaning as provided in
Section 1.414(c)-2(b)(2)(i) of the Treasury Regulations, provided that the language “at least 20 percent” is used instead of “at least 80 percent” each place it appears in Section 1.414(c)-2(b)(2)(i) of the Treasury Regulations. 

7.15    Governing Law; Severability. The Plan and all determinations made and actions taken
thereunder shall be governed by the internal substantive laws, and not the choice of law rules, of the State of New York and construed accordingly, to the extent not superseded by applicable federal law. If any provision of the Plan shall be held
unlawful or otherwise invalid or unenforceable in whole or in part, the unlawfulness, invalidity or unenforceability shall not affect any other provision of the Plan or part thereof, each of which shall remain in full force and effect. 

  
 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]